Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT03162341Not ApplicableCompleted

Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit

Role: collaborator

NCT01466166Completed

Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout

Role: lead

All 2 trials loaded